Item 8.01. Other Events.

On June 1, 2021, Acorda Therapeutics, Inc. (the "Company") issued to the holders of its 6.00% Convertible Senior Secured Notes due 2024 (the "Notes") an aggregate of 1,635,825 shares of the Company's common stock (the "Shares"), in satisfaction of approximately $6.2 million in interest due under the Notes on such date. Pursuant to the indenture under which the Notes were issued, the Company may elect to pay interest in cash or shares of the Company's common stock based on the formula set forth in the indenture. In connection with the issuance of the Shares, an amount corresponding to the $6.2 million of accrued interest will be released from escrow and will be available to the Company for other purposes. The issuance of the Shares was exempt from registration pursuant to Section 4(a)(2) of the Securities Act of 1933.

Item 9.01. Financial Statements and Exhibits.





Exhibit No.   Description
4.1             Indenture, dated as of December 23, 2019, among the Company, the
              guarantors party thereto, and Wilmington Trust, National
              Association, as trustee and collateral agent   (incorporated by
              reference to Exhibit 4.1 to the Company's Current Report on Form 8-K
              filed on December 26, 2019).
4.2             Form of 6.00% Convertible Senior Secured Notes due 2024
              (included in Exhibit 4.1)
104           Cover Page Interactive Data File (formatted as inline XBRL and
              contained in Exhibit 101)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses